[Lectin-related use of mistletoe: an experimental form of treatment with preclinically demonstrated potential risks].
Gabius
S
S
Onkologische Schwerpunktpraxis, Rosenheim, Germany. gabius.sigrun@t-online.de
Gabius
H J
HJ
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D006801:Humans; D037102:Lectins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D051379:Mice; D008809:Mice, Inbred C3H; D014784:Mistletoe / Q000009:adverse effects; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008517:Phytotherapy / Q000009:adverse effects; D037121:Plant Lectins; D028321:Plant Preparations; D010940:Plant Proteins; D051381:Rats; D054790:Ribosome Inactivating Proteins, Type 2; D012307:Risk Factors; D014118:Toxins, Biological / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000473:pathology
D000276:Adjuvants, Immunologic; D037102:Lectins; D037121:Plant Lectins; D028321:Plant Preparations; D010940:Plant Proteins; D054790:Ribosome Inactivating Proteins, Type 2; D014118:Toxins, Biological; C009674:ribosome inactivating protein, Viscum